Advanced Search:
Equity Index

MITRA.BR - MITHRA

€0.22  0.0005 (0.23%)

Updated: 11:15 May 5, 2024 EST

Next Session's AI Forecast

-77.09%

Avg. Accuracy (AI)

€-0.06

Next Week's AI Forecast

16.67%

Trend's Accuracy (AI)

€-0.06

MITHRA's Position Within the Drug Manufacturers - Specialty & Generic Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

MITHRA - HISTORICAL DATA 6M

  • Last price

    €0.22

  • Daily change

    €0.0005

  • Previous Close

    €0.2215

  • Last Updated

    11:15 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 -0.25 -2.24 -1.87 -1.11

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0 2.25 5.07 4.19 4.43

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
N/A N/A 0% 3.03%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
% % %

RSI METRIC

RS Hour RSI Hour RS Day RSI Day

MITHRA Technical Analysis News

MITHRA

Rue Saint-Georges 5
Liège 4000
Belgium
32 4 349 28 22
https://www.mithra.com

Sectors: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Description

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

Corporate Governance

Mithra Pharmaceuticals SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

MITHRA'S HOLDERS RANK

List of holders with stock participation in MITHRA.

Holder Rank Holder Shares Date Reported % Out Value